CNTO 888) Concentration Time Data

Total Page:16

File Type:pdf, Size:1020Kb

CNTO 888) Concentration Time Data Pharmacokinetics and Pharmacodynamics The Journal of Clinical Pharmacology Utilizing Pharmacokinetics/Pharmacodynamics 53(10) 1020–1027 ©2013, The American College of Modeling to Simultaneously Examine Clinical Pharmacology DOI: 10.1002/jcph.140 Free CCL2, Total CCL2 and Carlumab (CNTO 888) Concentration Time Data Gerald J. Fetterly, PhD1, Urvi Aras, PhD1, Patricia D. Meholick, MS1, Chris Takimoto, MD, PhD2, Shobha Seetharam, PhD2, Thomas McIntosh, MS2, Johann S. de Bono, MD, PhD3, Shahneen K. Sandhu, MD3, Anthony Tolcher, MD4, Hugh M. Davis, PhD2, Honghui Zhou, PhD, FCP2, and Thomas A. Puchalski, PharmD2 Abstract The chemokine ligand 2 (CCL2) promotes angiogenesis, tumor proliferation, migration, and metastasis. Carlumab is a human IgG1k monoclonal antibody with high CCL2 binding affinity. Pharmacokinetic/pharmacodynamic data from 21 cancer patients with refractory tumors were analyzed. The PK/PD model characterized the temporal relationships between serum concentrations of carlumab, free CCL2, and the carlumab–CCL2 complex. Dose‐dependent increases in total CCL2 concentrations were observed and were consistent with shifting free CCL2. Free CCL2 declined rapidly after the initial carlumab infusion, returned to baseline within 7 days, and increased to levels greater than baseline following subsequent doses. Mean predicted half‐lives of carlumab and carlumab–CCL2 complex were approximately 2.4 days and approximately 1 hour for free CCL2. The mean dissociation constant (KD), 2.4 nM, was substantially higher than predicted by in vitro experiments, and model‐based simulation revealed this was the major factor hindering the suppression of free CCL2 at clinically viable doses. Keywords soluble ligand, PK/PD modeling, cytokine CC‐chemokine ligand 2 (CCL2), also known as monocyte chemoattractant protein‐1, is a CC‐chemokine which acts through chemokine receptor 2.1–3 CCL2 promotes tumor inflammation, survival, angiogenesis, and metastasis in a variety of cancer types, including breast,4,5 lung,6 esophageal,7,8 and gastric9 carcinomas, as well as 1PK/PD Core Facility, Department of Medicine, Roswell Park Cancer melanoma,10,11 squamous cell carcinoma of the head Institute, Buffalo, New York 2 and neck,12 and hemangiomas.13,14 CCL2 is an important Janssen Research & Development, LLC, Spring House, Pennsylvania 3Drug Development Unit, Royal Marsden NHS Foundation Trust and stimulator in a model of human tumor cell angiogene- The Institute of Cancer Research, Sutton, UK 4,5,15 sis, and it has been proven to be a potent attractor for 4START (South Texas Accelerated Research Therapeutics), San monocytes and macrophages, especially tumor‐associated Antonio, Texas macrophages that have been implicated in the promotion of tumor growth and metastasis.4,5,16 In malignant tumors, Submitted for publication 29 January 2013; accepted 23 June 2013. high levels of CCL2 have been correlated with active Corresponding Author: angiogenesis, stimulated cancer cell proliferation, en- Thomas Puchalski, PharmD, Biologics Clinical Pharmacology, Janssen hanced metalloproteinase production, tumor aggres- Research & Development, LLC, 1400 McKean Road, PO Box 776, siveness, poor prognosis, and early relapse in patients.4,5 Spring House, PA 19477. Email: [email protected] Carlumab (formerly CNTO 888) is a human immuno- Author disclosures: Chris Takimoto, Shobha Seetharam, Thomas globulin G1 kappa monoclonal antibody with activity McIntosh, Hugh M. Davis, Honghui Zhou, and Thomas A. Puchalski against the soluble ligand CCL2 and is currently being are or were employees of Janssen Research & Development, LLC. at the evaluated as a potential therapeutic agent for the treatment time of the study and own(ed) stock in Johnson & Johnson. Gerald J. of solid tumors. Carlumab can neutralize CCL2 activity in Fetterly declares no conflicts of interest. Urvi Aras is an employee of 17 Bristol Myers Squibb. Patricia D. Zagst declares no conflicts of interest. vivo by binding to free CCL2 in the blood. It also Johann S. de Bono declares no conflicts of interest. Anthony Tolcher inhibits macrophage infiltration, prevents tumor angio- serves as an uncompensated consultant to Janssen Research & genesis, and decreases tumor vessel density.18 Inhibiting Development, LLC. Shahneen K. Sandhu declares no conflicts of interest. Fetterly et al 1021 CCL2 has the potential to reduce the number of provided informed written consent before any study drug macrophages and monocytes infiltrating tumor tissue, was administered. thereby modulating tumor inflammation and potentially Carlumab was measured in serum using an electro- decreasing tumor cell proliferation. chemiluminescence‐based immunoassay (ECLIA) with a Twenty‐five percent of US Food and Drug Adminis- lower limit of quantification (LLOQ) of 0.078 mg/ml. The tration‐approved antibody products fall into an important carlumab–CCL2 complex was measured in serum using subclass of agents that target soluble ligands.19 In the an ECLIA with a LLOQ of 300 pg/ml. Free serum CCL2 oncology field, little data characterizing the effects of was assayed using an initial Protein A‐based separation antibody on the target ligand are available. Utilizing a method followed by analysis using a commercial CCL2 pharmacokinetics/pharmacodynamics (PK/PD) modeling ELISA assay kit with a LLOQ of 78 pg/ml. approach to examine the interaction between the antibody Samples were collected for carlumab PK analysis prior and the target can provide insight into the turnover of the to and immediately after completion of the IV infusion. target and the binding affinity of the antibody. Additionally, for the first and fourth infusion, samples The overall goal of this modeling exercise was to were collected at 4 and 24 hours post‐infusion, and on devise a carlumab dosing strategy that would optimally Days 8, 15, 18, 22, and 25 post‐infusion. decrease CCL2 concentrations and prolong the length of For determination of serum concentrations of free time that free CCL2 concentrations are suppressed. The CCL2 and the carlumab–CCL2 complex, samples were specific objectives of our analyses were (1) to develop a collected prior to the infusion, 24 hours post‐infusion, and mechanistic PK/PD model to simultaneously characterize on Days 8, 15, and 22 post‐infusion following the first the serum concentration‐time profiles of carlumab, free administration of carlumab. For the second and third CCL2, and the carlumab–CCL2 complex and (2) to administrations, samples were only collected prior to the simulate free CCL2 concentrations following administra- infusion. For the fourth administration, samples were tion of various carlumab dose regimens in order to gain a collected prior to the infusion and 24 hours post‐infusion. better understanding of the effects of carlumab on free Additional samples were collected during follow‐up visits CCL2 and the carlumab–CCL2 complex. at Weeks 8, 12, and 18. Modeling Software Methods Population PK/PD modeling and simulation were per- Phase 1 Study of Carlumab in Malignant Solid Tumors formed using the maximum likelihood estimation method Details of the study design and results will be reported (MLEM) in ADAPT 5. Statistical analyses and graphing elsewhere.20 In brief, this first‐in‐human study of were performed using SAS Version 9.1, and Prism 5 was carlumab was an open‐label, multiple administration, used for plotting model‐based simulations. ascending‐dose study designed to determine the safety and PK of carlumab. Patients received a 90‐minute IV PK/PD Model infusion of carlumab, followed by a 4‐week monitoring A PK/PD model that incorporated target binding was used period to assess the single‐dose PK profile of carlumab. to simultaneously characterize the concentration‐time Three subsequent doses of carlumab were administered profiles of carlumab, the soluble ligand target, CCL2, every 2 weeks following the end of the monitoring period. and the carlumab–CCL2 complex in serum (Figure 1). In the dose‐escalation phase of the study, a total of 5 Several models were tested that incorporated the cohorts were evaluated at doses of 0.3, 1, 3, 10, or 15 mg/ relationship between the drug and the drug–receptor kg. Three patients were included in each cohort dosed at complex, but ultimately a quasi‐equilibrium model of 3 mg/kg, and 6 patients were included in each of the 10 target‐mediated drug disposition (TMDD) was used to and 15 mg/kg dose cohorts. The dose‐expansion phase analyze the available data.21 consisted of patients receiving either 10 or 15 mg/kg of Based on the pharmacological mechanism of action of carlumab at 2‐week intervals. Data from only the dose‐ drug–receptor complexes described by TMDD, IV escalation phase were used to develop the PK/PD model administered carlumab may distribute to and from tissue due to the robust amount of carlumab, free CCL2, and binding sites (k3 and k4) or may be eliminated from the carlumab–CCL2 complex serum concentration‐time central compartment by degradation (kdeg). Carlumab, information available from this phase of the study. Key which has a half‐life of approximately 2.4 days, binds to patient eligibility criteria included the presence of type‐ free CCL2 ligands, which have half‐lives of approximately specific solid tumors that had progressed after all 1 hour when present in the blood. Free CCL2 is assumed to available standard therapy, and measurable or evaluable be produced at a zero‐order rate of Ksyn and has a baseline metastatic disease. The study was conducted in accor- value of Rss. Free CCL2 also is assumed to distribute dance with the principles of the Declaration of Helsinki between tumor tissue and blood, and is eliminated from the and was approved by institutional review boards. Patients blood at a rate of Kdeg,free ligand. The formed complex is 1022 The Journal of Clinical Pharmacology / Vol 53 No 10 (2013) Ksyn carlumab CCL2 Tumor / Tissue K K K Blood 3 4 2 KD carlumab CCL2 complex Drug Admin 1 mole of carlumab binds 1 mole of CCL2 Kdeg, Kdeg, Kdeg, carlumab-CCL2 carlumab free CCL2 complex Figure 1. Simultaneous PK/PD model of carlumab, free CCL2, and carlumab–CCL2 complex.
Recommended publications
  • Immunfarmakológia Immunfarmakológia
    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Imperfect Storm: Is Interleukin-33 the Achilles Heel of COVID-19?
    Viewpoint Imperfect storm: is interleukin-33 the Achilles heel of COVID-19? Gaetano Zizzo, Philip L Cohen The unique cytokine signature of COVID-19 might provide clues to disease mechanisms and possible future therapies. Lancet Rheumatol 2020 Here, we propose a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving Published Online all stages of COVID-19 disease (ie, asymptomatic, mild–moderate, severe–critical, and chronic–fibrotic). In suscep- October 9, 2020 tible individ uals, IL-33 release by damaged lower respiratory cells might induce dysregulated GATA-binding https://doi.org/10.1016/ S2665-9913(20)30340-4 factor 3-expressing regulatory T cells, thereby breaking immune tolerance and eliciting severe acute respiratory Temple Autoimmunity Center syndrome coronavirus 2-induced autoinflammatory lung disease. Such disease might be initially sustained by (G Zizzo MD, Prof P L Cohen MD) IL-33-differentiated type-2 innate lymphoid cells and locally expanded γδ T cells. In severe COVID-19 cases, the and Section of Rheumatology, IL-33–ST2 axis might act to expand the number of pathogenic granulocyte–macrophage colony-stimulating factor- Department of Medicine expressing T cells, dampen antiviral interferon responses, elicit hyperinflammation, and favour thromboses. In patients (Prof P L Cohen), Lewis Katz School of Medicine at Temple who survive severe COVID-19, IL-33 might drive pulmonary fibrosis by inducing myofibroblasts and epithelial– University, Philadelphia, mesenchymal transition. We discuss the therapeutic implications of these hypothetical pathways, including use of PA 19140, USA; and Unit of therapies that target IL-33 (eg, anti-ST2), T helper 17-like γδ T cells, immune cell homing, and cytokine balance.
    [Show full text]
  • Orphan Drug Dummy File
    Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in Sigma-Tau levocarnitine Carnitor 11/15/1989 valproic acid toxicity Pharmaceuticals, Inc. 2 1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving Pediatric thalidomide n/a 9/19/1988 bone marrow transplantation Pharmaceuticals, Inc. 3 A Diagnostic for the management Advanced Imaging Theranost 68 Ga RGD n/a 10/1/2014 of Moyamoya disease (MMD) Projects, LLC (AIP) 4 Cadila heat killed Mycobacterium w Pharmaceuticals immunomodulator Cadi Mw 9/3/2004 Active tuberculosis Limited, Inc. 5 Adjunct to cytokine therapy in the treatment of acute myeloid Histamine Ceplene 12/15/1999 leukemia. EpiCept Corporation 6 Adjunct to surgery in cases of rh-microplasmin, ocriplasmin Jetrea 3/16/2004 pediatric vitrectomy ThromboGenics Inc. 7 Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or Ferring Laboratories, Somatostatin Zecnil 6/20/1988 pancreas. Inc. Page 1 of 377 Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with Allos Therapeutics, efaproxiral n/a 7/28/2004 breast cancer Inc.
    [Show full text]
  • Interstitial Lung Disease : Changing Landscape
    Approach to Diagnosis and Management of Interstitial Lung Disease : Changing Landscape Girish B. Nair MD, FACP, FCCP No Conflicts Of Interest Objectives 1. Review the diagnostic approach to a patient with ILD 2. Identify the indications for surgical lung biopsy 3. Recognize the newer treatment options available for Idiopathic Pulmonary Fibrosis Murray & Nadel’s Textbook of Respiratory Medicine- 6th Edition Exposures Connective tissue Genetic Idiopathic • Drugs Diseases • FPF • Sarcoidosis • Hypersensitivity • Rheumatoid arthritis pneumonitis – bird, • Lupus • IIP molds • Scleroderma • Radiation • Sjogren’s syndrome • Infections • Mixed connective tissue disease Interstitial Lung Diseases Sarcoidosis Idiopathic ILD of Known Cause & Other Interstitial Other or Association Granulomatous Pneumonias Diseases Medications LAM Pulmonary LCH Radiation Eosinophilic Connective Tissue Pneumonias Disease Alveolar Proteinosis Vasculitis & DAH Genetic Syndromes Hypersensitivity Pneumonitis Pneumoconioses ATS/ERS Guidelines for IIP. AJRCCM. 2002;165:277-304. REVISED ATS/ERS CLASSIFICATION OF IDIOPATHIC INTERSTITIAL PNEUMONIAS: MULTIDISCIPLINARY DIAGNOSES Major idiopathic interstitial pneumonias Idiopathic pulmonary fibrosis Idiopathic nonspecific interstitial pneumonia Respiratory bronchiolitis–interstitial lung disease Desquamative interstitial pneumonia Cryptogenic organizing pneumonia Acute interstitial pneumonia Rare idiopathic interstitial pneumonias Idiopathic lymphoid interstitial pneumonia Idiopathic pleuroparenchymal fibroelastosis Unclassifiable
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Therapeutic Antibody
    www.creativebiolabs.net THERAPEUTIC ANTIBODY Tel: 1-631-871-5806 Fax: 1-631-207-8356 45-1 Ramsey Road, Shirley, NY 11967, USA DBA Italia s.r.l. Via Umbria, 10, 20090 Segrate (Milan) Tel: +39 02 26922300 Fax:+39 02 26923535 DBA Italia s.r.l. email: [email protected] Via Umbria, 10, 20090 Segrate (Milan) Tel: +39 02 26922300 Fax:+39 02 26923535 email: [email protected] Products List Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer a full range of therapeutic antibodies currently available for research of a wide variety of diseases. We guarantee generated endotoxin free antibodies are fully functional and ready to use in animal- based assays and clinical trials. I Autoimmune and Inflammatory Diseases Antibody Cat. No Product Name Related Disease Name/Clone Anti-Human ITGA4+ITGB7 TAB-H02 Abrilumab Ulcerative colitis Therapeutic Antibody Anti-Human TNF Therapeutic Adalimumab Juvenile Idiopathic Arthritis TAB-010 Antibody TAB-717 Anti-APP Therapeutic Antibody Aducanumab Alzheimer's disease Anti-Human SOST Therapeutic Postmenopausal women TAB-115 Antibody Blosozumab osteoporosis Anti-Human IL12+IL23 Briakinumab Crohn's disease TAB-103 Therapeutic Antibody Anti-Human IL17RA Therapeutic Brodalumab Psoriatic arthritis TAB-134 Antibody Anti-Human MCP-1 Therapeutic Carlumab Immune disease TAB-117 Antibody Anti-Human CD4 Therapeutic Cedelizumab Allograft rejection TAB-107 Antibody Anti-Human IL6 Therapeutic TAB-094 Clazakizumab Crohn's disease Antibody Anti-Human CD4 Therapeutic TAB-260 Tregalizumab Psoriasis Antibody Anti-Human ITGA4 Therapeutic TAB-022 Natalizumab Multiple sclerosis Antibody Anti-Human CD11a Therapeutic TAB-108 Odulimomab Allograft rejection Antibody TAB-772 Anti-CD20 Therapeutic Antibody Ocrelizumab Multiple sclerosis Anti-Human IGHE Therapeutic TAB-007 Omalizumab Allergic asthma Antibody Anti-Human IL4 Therapeutic TAB-221 Pascolizumab Allergy Antibody www.creativebiolabs.net 4 / 30 Products List II Cancers Antibody Cat.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]